University of Cambridge Enterprise
VC Fund
Cambridge, United Kingdom
University of Cambridge Enterprise is a VC fund in Cambridge focused on Biotechnology and Health Care. University of Cambridge Enterprise, also known as Cambridge Enterprise Seed Funds, consisting of the Challenge Fund and the Venture Fund, is a resource for members of the University of Cambridge and the Babraham Institute. Investments are priced and structured competitively with other sources of early stage seed capital in order to encourageco-investment, follow-on funding and commercialisation of University of Cambridge and Babraham Institute inventions.
- Total investments:
- 112
- Last investment:
- Lead investor:
- 37%
Last updated:
For AI agents: llms.txt
Industries University of Cambridge Enterprise invests in
Stages University of Cambridge Enterprise invests in
Countries University of Cambridge Enterprise invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
Investment Focus
Industry
- Biotechnology 28 (25%)
- Health Care 20 (18%)
- Software 12 (11%)
- Medical 10 (9%)
- Life Science 9 (8%)
Stage
- Seed 37 (33%)
- Series A 30 (27%)
- Pre-Seed 12 (11%)
- Series B 7 (6%)
- Funding Round 6 (5%)
Country
- United Kingdom 64 (57%)
- Germany 1 (1%)
- Ireland 1 (1%)
- United States 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Amanda Wooding
Deputy Head of Life Sciences
|
Deputy Head of Life Sciences | Total investments: 3 | Find email | |
|
Anne Dobrée
Head of Seed Funds
|
Head of Seed Funds | Total investments: 1 | Find email | |
|
Christian Pratt
Head of Marketing and Communications
|
Head of Marketing and Communications | Total investments: 0 | Find email | |
|
Emma Barker
Senior Commercialisation Associate
|
Senior Commercialisation Associate | Total investments: 0 | Find email | |
|
Georgina Weller
Office Manager
|
Office Manager | Total investments: 0 | Find email | |
| See all 16 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Nu Quantum is a telecommunications company that develops end-to-end quantum cryptography systems.It secures communications within and between cities through urban and satellite free-space optical links. The system helps with the realization of commercial deliverable photonic technologies by combining novel materials and semiconductor technology.This enables clients to secure the exchange of cryptographic keys for the ultra-sensitive detection of light.Yuri Andersson, Mete Atatüre, and Carmen Berraquero founded Nu Quantum in Cambridge, Cambridgeshire in 2018. | $71.1M / Series A / Dec 10, 2025 | |
|
|
Paragraf is the world’s leading graphene-based electronic device design, development and manufacturing company. Building on our proprietary process to grow graphene directly on standard semiconductor industry substrates, Paragraf has pioneered the delivery of two-dimensional technologies at scale. Paragraf’s high-quality graphene – integratablewith standard semiconductor tool process lines – has unlocked the incorporation of this remarkable material into both existing and new electronic devices and applications. Through our world-first dedicated graphene device foundry, Paragraf delivers high-performance, low-power technologies to multiple markets and offers two-dimensional-material foundry services to customers and partners, providing graphene in chips to their device requirements. | $55M / Series C / Aug 25, 2025 | |
|
|
xwatts is an intelligent energy management system that helps commercial buildings reduce costs and emissions. | $1.8M / Pre-Seed / Jul 18, 2024 | |
|
|
Wave Photonics utilizes computational techniques to accelerate integrated photonics product designs.The company is developing a platform that provides optimized designs and streamlined integration between the supply chain using a software tool for predicting the performance and variation of a component for a given fabrication process and anoptimizer to generate a foundry-specific component library.Wave Photonics is headquartered in Cambridge, UK | $5.7M / Seed / Jun 20, 2024 | |
|
|
Echion Technologies specializes in developing advanced anode materials for Li-ion batteries. Their XNO® material boasts faster charging times, longer lifespans, and improved safety compared to traditional options. Echion targets the heavy-duty electric vehicle market, aiming to improve efficiency and sustainability within the transportation sector. | $37M / Series B / Jun 13, 2024 | |
|
|
Zetta Genomics manages large-scale genomic data for precision medicine. The company employs distributed database technology and best practice security techniques to leverage genomic data benefits while preserving data privacy. Zetta Genomics was founded in 2018 and is based in Cambridge, England. | $2.3M / Seed / Feb 08, 2024 | |
|
|
Xampla creates plant protein material for commercial use. Our next generation material performs like synthetic polymers, but decomposes naturally and fully, without harming the environment. | $7M / Venture - Series Unknown / Jan 30, 2024 | |
|
|
T-Therapeutics is a expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. . | $59.6M / Series A / Nov 15, 2023 | |
|
|
VC-backed startup developing software solutions and tools for building and validating AI-based perception. The company's vision is to accelerate the deployment of affordable autonomy solutions for automotive and industrial applications. | $2M / Seed / Jun 29, 2023 | |
|
|
Planetary Processing provides an SDK for the creation and operation of massively-multiplayer online games. Simplifying the creation and maintenance of large online games allows game studios to focus on game development instead of infrastructure. | $1.3M / Pre-Seed / Jun 07, 2023 | |
| See all 112 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does University of Cambridge Enterprise invest in?
University of Cambridge Enterprise invests primarily in Biotechnology, Health Care and Software startups, most often at Seed and Series A stage. Most of the 112 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact University of Cambridge Enterprise?
Public channels for University of Cambridge Enterprise include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at University of Cambridge Enterprise?
The team at University of Cambridge Enterprise includes Amanda Wooding (Deputy Head of Life Sciences), Anne Dobrée (Head of Seed Funds) and Christian Pratt (Head of Marketing and Communications), among 16 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!